HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.

Abstract
Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal cancer and is often refractory to current therapies. Development of efficient therapeutic strategies against ESCC presents a major challenge. Glycogen synthase kinase (GSK)3β has emerged as a multipotent therapeutic target in various diseases including cancer. Here we investigated the biology and pathological role of GSK3β in ESCC and explored the therapeutic effects of its inhibition. The expression of GSK3β and tyrosine (Y)216 phosphorylation-dependent activity was higher in human ESCC cell lines and primary tumors than untransformed esophageal squamous TYNEK-3 cells from an ESCC patient and tumor-adjacent normal esophageal mucosa. GSK3β-specific inhibitors and small interfering (si)RNA-mediated knockdown of GSK3β attenuated tumor cell survival and proliferation, while inducing apoptosis in ESCC cells and their xenograft tumors in mice. GSK3β inhibition spared TYNEK-3 cells and the vital organs of mice. The therapeutic effect of GSK3β inhibition in tumor cells was associated with G0/G1- and G2/M-phase cell cycle arrest, decreased expression of cyclin D1 and cyclin-dependent kinase (CDK)4 and increased expression of cyclin B1. These results suggest the tumor-promoting role of GSK3β is via cyclin D1/CDK4-mediated cell cycle progression. Consequently, our study provides a biological rationale for GSK3β as a potential therapeutic target in ESCC.
AuthorsDilireba Bolidong, Takahiro Domoto, Masahiro Uehara, Hemragul Sabit, Tomoyuki Okumura, Yoshio Endo, Mitsutoshi Nakada, Itasu Ninomiya, Tomoharu Miyashita, Richard W Wong, Toshinari Minamoto
JournalScientific reports (Sci Rep) Vol. 10 Issue 1 Pg. 11807 (07 16 2020) ISSN: 2045-2322 [Electronic] England
PMID32678196 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Glycogen
  • Glycogen Synthase Kinase 3 beta
Topics
  • Adult
  • Aged
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • Biomarkers, Tumor
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Disease Models, Animal
  • Esophageal Neoplasms (drug therapy, genetics, metabolism, pathology)
  • Esophageal Squamous Cell Carcinoma (drug therapy, genetics, metabolism, pathology)
  • Female
  • Gene Expression
  • Glycogen (metabolism)
  • Glycogen Synthase Kinase 3 beta (antagonists & inhibitors, genetics, metabolism)
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Phosphorylation
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: